>>GAITHERSBURG, Md.--(BUSINESS WIRE)--Feb. 9, 2006--GenVec, Inc. (Nasdaq:GNVC - News) announced today that it has received initial funding of $300,000 to begin preliminary vector development with the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, in preparation for the manufacture of clinical grade adenovector-based influenza vaccines. This initial seasonal and pandemic flu vaccine research effort was agreed to through an extension of the $50 million subcontract issued and managed by SAIC-Frederick under which GenVec has been working to develop and manufacture adenovector-based HIV vaccines in collaboration with the VRC.
GenVec is a biopharmaceutical company developing novel therapies to improve patient care in the areas of cancer and cardiac disease, and to prevent vision loss. GenVec's vaccine program applies the company's unique delivery technology and 293-ORF6 cell line to develop vaccines against a variety of diseases, including HIV, malaria and foot and mouth disease. Additional information on GenVec and its portfolio of product candidates is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.<<
Not much money, but a good sign.
Cheers, Tuck |
